
Autobahn Therapeutics Presents Preclinical Elunetirom Data at ACNP Annual Meeting
Autobahn Therapeutics, a clinical-stage biotechnology company advancing restorative therapies for individuals living with neuropsychiatric and neuroimmunologic disorders, today announced the presentation of new preclinical data supporting its lead investigational compound, elunetirom, at the 64th Annual American College of Neuropsychopharmacology Annual…








